Early change in serum leucine-rich α-2-glycoprotein predicts clinical and endoscopic response in ulcerative colitis
Open Access
- 30 October 2024
- journal article
- research article
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 22 (4) , 473-483
Abstract
Background/Aims: Leucine-rich α-2-glycoprotein (LRG) is a new serum biomarker reflecting the disease activity of ulcerative colitis (UC), but its change during the acute phase has not been enough investigated. Methods: Patients with UC who initiated the induction therapy with steroid or advanced therapy (biologics or Janus kinase inhibitors) were prospectively enrolled. Associations of LRG, C-reactive protein (CRP) and fecal calprotectin (FC) at baseline, week 1, and week 8 with clinical remission at week 8 and subsequent endoscopic improvement within 1 year (Mayo endoscopic subscore of 0 or 1) were assessed. Results: A total of 143 patients with UC were included. LRG and CRP at week 1 were significantly lower in the clinical remission group than in the non-remission group (LRG, 20.6 μg/mL vs. 28.4 μg/mL, P< 0.001; CRP, 0.9 mg/dL vs. 2.3 mg/dL, P< 0.001) while FC demonstrated the difference between groups only at week 8. The area under the curves of week 1 LRG, CRP, and FC for week 8 clinical remission using the receiver operating characteristic curves analysis were 0.68, 0.71, and 0.57, respectively. Furthermore, LRG and CRP predicted subsequent endoscopic improvement as early as week 1, while FC was predictive only at week 8. Conclusions: LRG can be an early-phase biomarker predicting subsequent clinical and endoscopic response to induction therapy.Keywords
Funding Information
- Kitasato University Kitasato Institute Hospital (19003)
This publication has 31 references indexed in Scilit:
- Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET studyJournal of Gastroenterology, 2021
- Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn's disease activityJGH Open, 2018
- First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysisJournal of Gastroenterology, 2015
- Correlations of C-reactive Protein Levels and Erythrocyte Sedimentation Rates with Endoscopic Activity Indices in Patients with Ulcerative ColitisDigestive Diseases and Sciences, 2013
- Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel diseaseInflammatory Bowel Diseases, 2012
- Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitisInflammatory Bowel Diseases, 2012
- Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitisJournal of Crohn's and Colitis, 2012
- Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitisJournal of Gastroenterology, 2010
- Pathogenic implications for autoantibodies against C-reactive protein and other acute phase proteinsClinica Chimica Acta, 2007
- Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic diseaseInternational Journal of Colorectal Disease, 2006